{
  "docId": "019dd923-622c-750b-8b9a-3bcd52c6e583",
  "docSlug": "f06b0b5d2079",
  "documentTitle": "Soleno Therapeutics (SLNO)",
  "authorId": "58_Scorpion_Capital",
  "authorName": "Scorpion Capital",
  "documentKindSlug": "activist-deck",
  "documentKindLabel": "Activist deck",
  "sourceTypeSlug": "short_seller",
  "sourceTypeLabel": "Short seller",
  "presentationDate": "2025-08-15 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.3333334,
  "pageNumber": 185,
  "pageCount": 415,
  "prevPage": 184,
  "nextPage": 186,
  "slideType": "expose_contradiction",
  "function": "expose_contradiction",
  "density": "dense",
  "nDataPoints": 24,
  "notes": "The slide uses a red box to highlight the specific data points (weeks 12-16 of the withdrawal period) that the author claims are the basis for the company's efficacy argument.",
  "elementsJson": [
    "headline_text",
    "paragraph",
    "screenshot",
    "footnote"
  ],
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019dd923-622c-750b-8b9a-3bcd52c6e583/185",
  "deckHref": "/decks/019dd923-622c-750b-8b9a-3bcd52c6e583",
  "deckJsonHref": "/decks/019dd923-622c-750b-8b9a-3bcd52c6e583.json",
  "deckAnchorHref": "/decks/019dd923-622c-750b-8b9a-3bcd52c6e583#slide-185",
  "components": [
    {
      "bbox": null,
      "kind": "callout",
      "text": "the basis of efficacy and FDA approval is nothing more than a sharp and rather fortuitous separation in HQ-CT scores in placebo arm (n=39) vs. DCCR (n=38) in the last 4 weeks of the 16-week withdrawal period (+4.5 pbo, +0.4 DCCR).",
      "attrs": null,
      "subkind": null,
      "toolName": "Visual emphasis",
      "toolSlug": "visual-emphasis",
      "confidence": null,
      "componentId": "019dd953-64ce-7561-b2a6-9c6347e23f54",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.55,
        "w": 0.86,
        "x": 0.07,
        "y": 0.325
      },
      "kind": "chart",
      "text": "HQ-CT Total Scores Over Time",
      "attrs": null,
      "subkind": "line",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "45baadba-9182-4a65-ba6b-9db0b250b286",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": null,
      "kind": "metric",
      "text": "HQ-CT Total Score",
      "attrs": null,
      "subkind": "primary",
      "toolName": "Quantification",
      "toolSlug": "quantification",
      "confidence": null,
      "componentId": "019dd953-64ce-7561-b2a6-a05aa1a0e8f7",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.03,
        "w": 0.56,
        "x": 0.07,
        "y": 0.27
      },
      "kind": "paragraph",
      "text": "DCCR clinical studies – Soleno investor presentation",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "96985a9d-8d18-414f-b0e8-86d70a87876d",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.02,
        "w": 0.45,
        "x": 0.07,
        "y": 0.95
      },
      "kind": "source-note",
      "text": "Source: https://investors.soleno.life/static-files/48405466-3bcb-41d8-ae9e-76f388652c12",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "d23ab3e8-a398-46ff-a1da-dd8fe558d6bf",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.86,
        "x": 0.07,
        "y": 0.07
      },
      "kind": "title",
      "text": "The phase 3 and withdrawal studies lack credibility and were plagued with numerous problems, which we shall cover. but we start by noting that the basis of efficacy and FDA approval is nothing more than a sharp and rather fortuitous separation in HQ-CT scores in placebo arm (n=39) vs. DCCR (n=38) in the last 4 weeks of the 16-week withdrawal period (+4.5 pbo, +0.4 DCCR).",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "d1e8a7ee-ebbc-4918-bd4b-fa974d143ca9",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [
    {
      "name": "fraud-exposure",
      "slug": null,
      "matchId": "adf47410-3c1c-4f60-91ed-c206741696ac",
      "evidence": "The slide explicitly frames the company's primary efficacy data as 'fortuitous' and 'nothing more than' a narrow separation, aiming to undermine the credibility of the clinical trial results.",
      "confidence": 0.9
    }
  ],
  "arcBeats": [],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}